Screening In-Depth Focus 2019
This in-depth focus discusses screening and the uses of phenotypic profiling in drug discovery. Also examined is the role that CRISPR/Cas9 gene editing and native mass spectrometry play.
List view / Grid view
Articles
Imaging In-Depth Focus 2019
In this in-depth focus, the challenges of imaging are explored including how to develop high-resolution images. Also discussed are new imaging technologies to aid drug discovery.
Phenotypic profiling in drug discovery
Image-based phenotypic profiling of small molecules has been used for identification and characterisation of small molecules in drug discovery and can provide important insights into their mechanisms of action (MOA). This article discusses the use of phenotypic profiling in drug discovery and how machine-learning algorithms could help improve objectivity, processing…
Stem Cell In-Depth Focus 2019
This in-depth focus looks at the modification of stem cells to facilitate their efficient delivery to tumours, highlighting the new development of pluripotent stem cells.
Drug Target Review – Issue 2 2019
In this issue: novel approaches to produce radiolabelled antibodies, the use of CRISPR/Cas9 to accelerate the development of targeted therapies and utilisation of stem cells to study the effects of cannabis on neuronal development.
AI-driven automated chemistry as a tool to accelerate drug discovery
Typically, early drug discovery campaigns start with the screening of chemical libraries to identify candidate chemotypes modulating a particular target and/or phenotype. Success of the primary screening depends on multiple factors related to both biology and chemistry. These include the target’s druggability, sensitivity and specificity of assay system, composition and…
Squaring the circle – cancer vaccines
By the 1890s William B. Coley had injected streptococcal organisms in patients with solid tumours (“Coley’s Toxins”) to activate the immune system. Coley (1862-1936) was an American bone surgeon and pioneer of cancer immunotherapy. He was convinced that post-surgical infections had helped patients to recover better from their cancer by…
Farther than fat: how lipids change research
Today we are beginning to realise that lipids have been inadequately represented in biological and medical research. For decades, studies in the fields of DNA and proteins have been pushed but despite these adverse conditions, lipid research has made pioneering discoveries over the course of the last seven years. These…
Why do we have no effective treatments for osteoarthritis?
Osteoarthritis (OA) is a painful and debilitating disease of articular joints.1,2 Its clinical prevalence is as high as 21.6 percent of the population in the United States,3 which constitutes direct health costs of over 80 billion US dollars annually.4
Realising the promise of laboratory automation in biomedical research
Automation offers a choice of powerful ways to design and execute high-quality laboratory research. The use of lab automation is now pervasive in biomedical labs, offering versatile platforms on which to perform an ever‑expanding array of tasks free of human errors, and a unique means to address the problems associated…
Transforming drug discovery, development and delivery with flow chemistry
Flow chemistry is on the rise thanks to the commercial availability of benchtop continuous flow systems that has driven widespread adoption of the technique across a broad range of applications in both academia and industry. In particular, flow chemistry is delivering significant benefits in the area of drug discovery and…
The importance of characterising chemical starting points of drugs using appropriate in vitro ADME-toxicity assays
Over the past 30 years, one strategy the pharmaceutical industry has adopted in the drug discovery process has been to “fail early, fail often”.1,2 As most molecules in the early stages of drug discovery will have sub-optimal characteristics, significant modification is necessary to improve their properties.
Drug discovery from the age of information to the age of intelligence
Data drives drug discovery, yet it continues to be among the biggest challenges faced by the industry.1 Experiments are often not repeatable and data interpretation is subject to the biases and limitations of human beings.
Cell line development – global market drivers, trends and its impact on improving biologics development from early phase to IND during the drug discovery process
Cell line development is a major step for examining the efficiency of drug discovery, toxicity and in vitro testing. It reduces time, effort and cost, which minimises the chance of research drugs failing at the clinical trial stage. This stage involves the production of recombinant proteins such as monoclonal antibodies,…
Lab Automation In-Depth Focus 2019
In this In-Depth Focus: realising the promise of laboratory automation in biomedical research, drug discovery from the age of information to the age of intelligence, and transforming drug discovery, development and delivery with flow chemistry.
